Plasma cytokine levels reveal deficiencies in IL-8 and gamma IFN in Long-COVID

2	Plasma cytokine levels reveal deficiencies in IL-8 and
3	gamma interferon in Long-COVID
4	
5	
6	
7	
8	
9	
10	
11 12	
13 14	Authors
15 16 17	Elizabeth S. C. P. Williams ¹ , Thomas B. Martins ² , Harry R. Hill ^{2,3,4} , Mayte Coiras ⁵ , Kevin S. Shah ³ , Vicente Planelles ¹ (*), Adam M. Spivak ^{1,3} (*)
18 19	Affiliations
20 21 22 23 24 25 26 27 28 29 30 31 32 33	 ¹University of Utah School of Medicine, Department of Pathology, 15 North Medical Drive East, Salt Lake City, UT 84112. ²ARUP Institute for Clinical and Experimental Pathology, 1950 Circle of Hope Drive, Salt Lake City, UT 84112. ³ University of Utah School of Medicine, Department of Internal Medicine, Salt Lake City, UT 84112. ⁴University of Utah School of Medicine, Departments of Pathology and Pediatrics, Emeritus, Salt Lake City, UT 84112 ⁵AIDS Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Avda. De Monforte de Lemos, 5, 28029, Madrid, Spain. *Address correspondence to Adam.spivak@hsc.utah.edu and vicente.planelles@path.utah.edu

Plasma cytokine levels reveal deficiencies in IL-8 and gamma IFN in Long-COVID

1 Abstract

$\begin{array}{c}2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\end{array}$	Up to half of individuals who contract SARS-CoV-2 develop symptoms of long-COVID approximately three months after initial infection. These symptoms are highly variable, and the mechanisms inducing them are yet to be understood. We compared plasma cytokine levels from individuals with long-COVID to healthy individuals and found that those with long-COVID had 100% reductions in circulating levels of interferon gamma (IFN γ) and interleukin-8 (IL-8). Additionally, we found significant reductions in levels of IL-6, IL-2, IL-17, IL-13, and IL-4 in individuals with long-COVID. We propose immune exhaustion as the driver of long-COVID, with the complete absence of IFN γ and IL-8 preventing the lungs and other organs from healing after acute infection, and reducing the ability to fight off subsequent infections, both contributing to the myriad of symptoms suffered by those with long-COVID.
18	Keywords: Long-COVID, PASC, IL-8, IFNγ, Immune Exhaustion, SARS-CoV-2
19	
20	
21	
22 23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	

Plasma cytokine levels reveal deficiencies in IL-8 and gamma IFN in Long-COVID

1 Introduction

- 2 COVID-19, caused by a novel coronavirus known as severe acute respiratory syndrome
- 3 coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health
- 4 Organization March 11th, 2020[1]. COVID-19 is responsible for 538.6 million infections
- 5 and over 6.3 million deaths worldwide as of June 18th, 2022[2]. For up to half of
- 6 individuals who contract the virus, acute SARS-CoV-2 infection is followed by persistent
- 7 health issues [3]. These individuals suffer a myriad of symptoms that affect their daily
- 8 lives, including fatigue and post-exertional malaise, respiratory and cardiac symptoms,
- 9 neurological symptoms, digestive symptoms, and more (Table 1)[4, 5].

10 11

Table 1. Long-COVID Symptoms							
Categories:	Neurocognitive:	Respiratory:	Psychological:	Other:			
	Brain fog	General fatigue	Post-traumatic stress disorder	Ageusia			
	Dizziness	Dyspnea	Anxiety	Anosmia			
	Loss of attention	Cough	Depression	Parosmia			
Symptoms:	confusion	Throat pain	Insomnia	Skin rash			
Symptoms.	Autonomic:	Gastrointestinal:	Musculoskeletal:				
	Chest pain	Diarrhea	Myalgias				
	Tachycardia	Abdominal pain	Arthralgias				
	palpitations	Vomiting					
Most commonly reported symptoms associated with long-COVID[4, 5].							

- 14 Several names are in use to describe this post-viral syndrome, including long-haul
- 15 COVID, post-acute sequalae of SARS-CoV-2 (PASC), and long-COVID. The
- 16 mechanisms driving long-COVID are still poorly understood. We defined Long-COVID
- 17 syndrome patients as those who fulfilled one of the following criteria: (a) individuals
- 18 whose symptoms never resolved following acute infection; (b) individuals whose
- 19 COVID-19 symptoms resolved but subsequently returned; or (c) individuals who
- 20 developed new symptoms approximately three months after initial infection[6, 7].
- 21 Severity of symptoms during acute infection does not appear to predispose to
- 22 development of long-COVID. Both asymptomatic individuals and those hospitalized due
- 23 to severe complications develop long-COVID at similar rates[3, 8, 9].
- 24
- 25 Post-viral sequelae of human coronavirus (HCOV) infections have been well
- documented [10-12]. Both the severe acute respiratory syndrome coronavirus (SARS-
- 27 CoV) outbreak in 2003[13-17] and the Middle Eastern respiratory syndrome coronavirus
- 28 (MERS-CoV) outbreak starting in 2012[<u>18-20</u>] caused post-viral syndromes with similar
- symptom profiles to those experienced by individuals with long-COVID[21]. Additionally,
- 30 other human coronaviruses; especially HCOV 229E and HCOV NL63; that did not reach
- 31 pandemic status, have been implicated as the etiology of Kawasaki Syndrome[<u>10</u>, <u>11</u>].

Plasma cytokine levels reveal deficiencies in IL-8 and gamma IFN in Long-COVID

1 Chikungunya Virus also induces a post-viral syndrome, which presents with symptoms 2 reminiscent of rheumatoid arthritis[22-25].

3

4 Long-COVID symptomatology bears similarities to myalgic encephalomyelitis/ chronic

- 5 fatigue syndrome (ME/CFS). ME/CFS is characterized by 6 months or more of constant
- 6 or relapsing bouts of excessive fatigue, cognitive impairment, post-exertional malaise,
- 7 unrefreshing sleep, headaches, and neuroendocrine and immune alterations[26-30]. The
- 8 number of people affected by ME/CFS is growing each year, currently affecting 0.3%-
- 9 2.5% of the population globally, depending on the diagnostic criteria used[<u>31</u>, <u>32</u>]. The
- 10 heterogeneous symptoms of ME/CFS are linked to dysregulation of multiple biological
- systems including the immune system and inflammation [33-37], cytokines [27, 32, 38],
- metabolism[34, 39-42], mitochondrial function[34, 39, 43], oxidative stress[34, 36],
- apoptosis[<u>34</u>, <u>36</u>], and circadian rhythm[<u>34</u>, <u>44</u>]. Additionally, research into cytokine
 levels as biomarkers for ME/CFS diagnosis or severity metrics has yielded conflicting
- reports, for a thorough review please see Blundell *et al.* 2015[32]. There are also
- 16 disparate theories regarding the origin of ME/CSF including dysbiosis of one's
- 17 microbiome[41, 45-47], and as a post-viral syndrome following infection with Epstein
- 18 Barr Virus[48-51].
- 19
- 20 Based on the pro-inflammatory basis of other post viral syndromes, we hypothesized
- 21 that Long-COVID is caused by abnormal, sustained, elevated levels of pro-inflammatory
- 22 cytokines present in the blood after acute SARS-CoV-2 infection has abated. To test
- this, we assayed plasma from 15 healthy individuals and compared it to plasma from 12
- 24 patients at the University of Utah's Long-COVID Clinic.
- 25

26 Materials and Methods

27

28 Study Subjects

- 29 We obtained healthy donor blood samples from individuals who were recruited under
- 30 University of Utah Institutional Review Board (IRB) protocol 131664. These individuals
- 31 were recruited from Salt Lake City, UT and the surrounding metro area between May of
- 32 2020 and December of 2021. For the purposes of this study, we define "healthy" as
- individuals who were uninfected or had been infected but recovered without the
- 34 sequalae of long-COVID.
- 35
- In the fall of 2021, the University of Utah opened a Long-COVID registry (IRB 140978).
- 37 Individuals attending University of Utah Comprehensive COVID clinic or self-identified
- 38 with Long-COVID can enroll in the registry, which includes a detailed symptom and
- 39 health survey and blood draw for biobanking of plasma and PBMCs at the Cellular
- 40 Translational Research Core (CTRC) at the University of Utah.
- 41

42 Blood and Tissue Samples

- 43 15 mL of total blood was collected by phlebotomy-certified research staff into two BD
- 44 Vacutainer EDTA Additive Blood Collection Tubes. Tubes were gently inverted 8-times
- to mix the blood and EDTA and were then centrifuged at 150g for 20 minutes at room
- 46 temperature. Blood plasma was collected following centrifugation and cryopreserved in

Plasma cytokine levels reveal deficiencies in IL-8 and gamma IFN in Long-COVID

- 1 sterile cryovials at -80°C. Peripheral blood mononuclear cells (PBMCs) were isolated by
- 2 Ficoll density gradient (Histopaque-1077, Sigma), and were cryopreserved in 1mL
- 3 aliquots in 80% complete culture media (endothelial cell media), 10% fetal bovine serum
- 4 (FBS), and 10% dimethyl sulfoxide (DMSO) in sterile cryovials at -80°C.
- 5

6 Determination of Cytokine Concentration in Plasma

- 7 The Luminex based (Luminex Corp, TX) multiplexed cytokine assay was performed
- 8 using a modified version of our previously published method[52, 53]. Briefly, monoclonal
- 9 antibodies to human IL-2, sIL-2r, IL-4, IL-6, IL-8, IL-10, TNFα (BD Biosciences, Franklin
- 10 Lakes, NJ), IL-13, IL-17, IFNγ (eBioscience-ThermoFisher Scientific, Waltham, MA),
- and IL-1 β , IL-5 (R&D Systems Minneapolis, MN), IL-12 p35/p70 (Cell Sciences,
- 12 Newburyport MA), were covalently coupled to MagPlex microsphere particles (Luminex
- 13 Corporation) using a 2-step carbodiimide reaction, as previously described (Staros,
- 14 Wright et al. 1986). A standard curve was generated by mixing known concentrations of
- 15 recombinant human cytokine receptor IL-2r (R&D Systems), and recombinant human
- 16 cytokines IL-1 β , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17, TNF α and IFN γ
- 17 (R&D Systems). Biotinylated secondary antibodies were purchased from the following
- 18 sources: eBioscience-ThermoFisher Scientific (IL-1 β , IL-4, IL-6, TNF α , IL-12p70, IFN γ ,
- 19 IL-13, IL-17) and BD Biosciences (IL-2, IL-5, IL-8, IL-10, IL-2r). Performance parameters
- 20 including specimen dilution/recovery, detection capability, precision, interference due to
- 21 hemolysis, specimen stability, and linearity were validated following Clinical &
- 22 Laboratory Standards Institute (CLSI) guidelines.
- 23

24 Statistical Analysis

- 25 The individual cytokine values for the healthy and Long-COVID cohorts were analyzed
- 26 for statistical significance using unpaired, two-tailed, nonparametric Mann-Whitney tests
- 27 with Prism 9.0 (GraphPad Software, San Diego, CA, USA).
- 28
- 29

30 Results

- 31 Our long-COVID cohort included 12 individuals, who we compared to 15 matched,
- 32 healthy controls (Table 2). The cytokines assayed included IL-1β, IL-2, sIL-2R, IL-4, IL-
- 33 5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17, IFNγ, and TNFα. Figure 1 shows the plasma
- 34 concentration in pg/ml of each cytokine. Individuals in the long-COVID cohort have
- 35 decreased levels in most cytokines tested. Most notably, individuals with long-COVID


Table 2. Cohort Demographics

- 36 have a 100% reduction
- 37 in plasma levels of
- 38 interferon gamma (IFNγ)
- 39 and IL-8, yielding p-
- 40 values of <0.0001 and
- 41 0.0011, respectively
- 42 (Figure 1).
- 43
- 44
- 45

	All Participants	Se	Age Ranges	
		Male	Female	
n	27	7	20	23-70
Healthy	15	7	8	27-65
Long- COVID	12		12	23-70

6

Plasma cytokine levels reveal deficiencies in IL-8 and gamma IFN in Long-COVID



Plasma cytokine levels reveal deficiencies in IL-8 and gamma IFN in Long-COVID

Table 3. Statistical Summary of Cytokine Comparison								
Cytokine	Hea	althy	Long-	Long- % Change in Long-			% Change in Long-	
	(M+F)	(F only)	COVID	COVID o	compared to COVID compared to		compared to	
n=	15	8	12 Healthy (M+F) Healthy (F o		iy (F only)			
	Median	Median	Median	% Change	p=	% Change	p=	
IFNγ	4.586	5.263	0.0000	-100%	<0.0001****	-100%	<0.0001****	
IL-8	1.700	0.3848	0.0000	-100%	0.0011**	-100%	0.0144*	
IL-6	1.248	1.317	0.3685	-70.46%	0.0016**	-72.05%	0.0062**	
IL-2	2.953	3.567	1.588	-46.19%	0.0285*	-55.45%	0.0028**	
IL-17	0.8802	1.024	0.4846	-44.94%	0.0082**	-52.68%	0.0191*	
IL-13	9.564	13.40	5.462	-42.89%	0.0176*	-59.23%	0.0189*	
IL-4	2.262	2.969	1.653	-26.92%	0.0266*	-44.32%	0.0362*	
sIL-2R	229.2	205.6	174.2	-24.03%	0.1138	-15.32%	0.4269	
IL-1β	6.425	7.469	5.153	-19.8%	0.2701	-31.01%	0.0779	
IL-12	2.687	2.900	2.162	-19.53%	0.1320	-25.43%	0.0788	
IL-10	1.494	1.598	1.219	-18.38%	0.0717	-23.69%	0.1506	
IL-5	0.5346	0.6157	0.4542	-14.71%	0.0884	-26.23%	0.0323*	
TNFα	2.812	3.397	2.909	3.47%	0.7815	-14.35%	0.7201	
Percent change and p-values for comparisons between the healthy cohort and the long-								

Percent change and p-values for comparisons between the healthy cohort and the long-COVID cohort, as well as between the healthy (females only) and the long-COVID cohort.

1 In addition, individuals with long-COVID have a 70% reduction in levels of IL-6. Levels

2 of IL-2, IL-17, and IL-13 were reduced more than 40% in individuals with long-COVID

3 (p-values 0.0285, 0.0082, and 0.0176, respectively; Figure 1; Table 3). Individuals with

4 long-COVID also had a reduction in levels of IL-4 (26%; p = 0.0266). Differences in

5 plasma levels of soluble IL-2 receptor (sIL-2R), IL-1β, IL-12, IL-10, IL-5, and TNFα

6 between the long-covid and healthy groups were not statistically significant.

7

8 Given that all the participants in the long-COVID group (12 out of 12) were female

9 (Table 2), we sought to investigate whether the observed cytokine deficits in the long-

10 COVID group were perhaps linked to biological sex. To do this, we performed two

11 comparisons. First, we compared cytokine levels between males and females in the

12 healthy group. These results showed that in healthy individuals, 12 out of the 13

13 cytokines assayed were not significantly different between healthy males and females.

14 One cytokine, IL-2, was 42% lower in healthy males than in healthy females (p =

- 15 0.0367; Figure 3; Table 4).
- 16

17 Secondly, we compared cytokine levels between the long-COVID group (all females)

and the female participants in the healthy group (n = 8). We continue to observe a 100%

19 reduction in IFNγ and IL-8 levels with p-values of <0.0001 and 0.0144, respectively


20 (Figure 2). We also observed a 72% reduction in IL-6 (p = 0.0062), 55% lower levels of

21 IL-2 (p = 0.0028), a 59% decrease in IL-13 levels (p = 0.0189), and IL-4 levels are

reduced by 44% (p = 0.0362) in females with long-COVID (Figure 2; Table 3). One

notable difference in the results from this female-female analysis is that the observed

decrease in IL-5 levels (26%) in long-COVID females becomes statistically significant with a p-value of 0.0323, whereas the decrease between the healthy cohort when it



Plasma cytokine levels reveal deficiencies in IL-8 and gamma IFN in Long-COVID

Plasma cytokine levels reveal deficiencies in IL-8 and gamma IFN in Long-COVID

1

- 2 contains both males and
- 3 females and the long-
- 4 COVID cohort is only
- 5 14% and is not
- 6 statistically significant
- 7 (Figure 1; Table 3). The
- 8 changes observed in slL
- 9 2R, IL-1β, IL-12, IL-10,
- 10 and TNF α levels remain
- 11 not statistically significant
- 12 whether the healthy
- 13 cohort includes the males
- or not (Figure 2; Table 3)
- 15
- 16
- 17
- 18

19

Cytokine	Heal	lthy	% Change in Males compared to Females			
	Females	Males				
n=	8	7	compared			
	Median	Median	% Change	p=		
IL-2	3.567	2.04	-42.81%	0.0367*		
IFNγ	5.263	3.657	-30.51%	0.2793		
TNFα	3.397	2.419	-28.79%	0.6929		
IL-13	13.40	9.564	-28.62%	0.0533		
IL-1β	7.469	5.479	-26.63%	0.1786		
IL-5	0.6157	0.4542	-26.23%	0.1304		
IL-4	2.969	2.262	-23.82%	0.2678		
IL-6	1.317	1.016	-22.87%	0.9259		
IL-10	1.598	1.322	-17.27%	0.8872		
IL-12	2.900	2.476	-14.62%	0.1131		
IL-17	1.024	0.8802	-14.04%	0.8424		
sIL-2R	205.6	264.9	22.37%	0.0541		
IL-8	0.3848	3.356	88.52%	0.0667		
Percent change and p-values for comparisons between males and females within the healthy cohort.						

20 Discussion21

Upon infection with SARS-CoV-2 the innate immune system recognizes both pathogenand damage- associated molecular patterns (PAMPs and DAMPs, respectively) and responds by activating the NLRP3 (NOD-, LRR-and pyrin domain-containing protein 3) inflammasome[54, 55]. Monocytes and macrophages respond to PAMPs and DAMPs by

secreting type I IFN and the pro-inflammatory cytokines IL-1, IL-2, IL-6, IL-12, and

27 TNF α [54, 56]. To evaluate the possibility that dysregulated secretion of pro-inflammatory

28 cytokines can be observed in the context of long COVID, we measured levels of 13

29 plasma cytokines via Luminex assay in samples from 12 donors diagnosed with long-

30 COVID and compared them to 15 healthy controls (Table 2). All the statistically

significant differences between the long-COVID cohort and healthy controls represented
 reductions in cytokine levels rather than the expected increases based on previous

33 studies of other post-viral syndromes (Figure 1; Table 3)[32, 57].

34

35 Pro-inflammatory cytokines have been implicated in multiple aspects of acute COVID-

19 pathogenesis. For example, increased levels of IL-1 β are linked to lymphopenia in

37 COVID-19 patients, presumably due to ongoing inflammation-induced pyroptosis[54,

38 <u>58</u>]. Macrophages express angiotensin-converting enzyme 2 (ACE2) receptors, making

39 it possible for SARS-CoV-2 to directly infect them, and, as COVID-19 severity

40 increases, activated macrophages congregate in the lungs, where even if not

41 productively infected, an abortive infection of macrophages by SARS-CoV-2 is sufficient

42 to induce cytokine storm[54, 59, 60]. Lastly, supporting the importance of Th17 in the


43 pathogenesis of COVID-19, is research showing that there are increased numbers of

44 Th17 cells present in blood samples of COVID-19 patients[54, 61].

45

46 The two most drastically decreased cytokines in our study were IFN γ and IL-8, each

47 reduced by 100% in our long-COVID cohort. IL-8 is produced by many cell types,



Compariso n of cytokines between the healthy females (n = 8) healthy males (n = 8)

7). (*) p ≤ 0.05.

Plasma cytokine levels reveal deficiencies in IL-8 and gamma IFN in Long-COVID

Plasma cytokine levels reveal deficiencies in IL-8 and gamma IFN in Long-COVID

1 including epithelial cells, fibroblasts, endothelial cells, macrophages, lymphocytes and 2 mast cells[<u>62</u>]. The secretion of IL-8 is induced in part by levels of IL-1 β . However we 3 found that there is no significant difference in IL-1 β levels between individuals with long-4 COVID and healthy controls.

5

6 Also referred to as the neutrophil chemotactic factor, IL-8 recruits neutrophils and NK-7 cells to sites of inflammation where they can clear infected cells and promote wound 8 healing. It is possible that the apparent lack of IL-8 in long-COVID patients may be 9 responsible for at least some of the debilitating symptoms including post-exertional malaise, fatigue, persistent cough, shortness of breath and chest pain. In this scenario, 10 11 the acute SARS-CoV-2 infection damages the lungs, the cytokine milieu unfolds as 12 described above, recruiting cells to the site of damage where the cells can either (a) 13 help control the infection and induce a wound healing environment and the individual 14 recovers normally; or (b) the infection causes abundant cellular infiltration leading to a 15 high concentration of immune cells in a relatively small physical space, ultimately causing more tissue damage, which is not efficiently repaired in the absence of IL-8. 16 17 Predictably, under scenario 'b' the individual remains having difficulty with oxygen transfer from the lungs into the blood stream. Therefore, if the macrophages and other 18 19 cells that secrete IL-8 become exhausted or are otherwise incapable of secreting IL-8, 20 neutrophils will not be recruited to assist in the wound healing process in the lung once 21 the infection has been cleared [63]. Scenario 'b' therefore emerges as a potential model 22 to explain certain long-COVID complications based on lack of IL-8. 23

24 IFNy is secreted by the innate immune natural killer cells (NK) and natural killer T cells 25 (NKT) as well as the adaptive immune CD4+ Th1 and CD8+ cytotoxic T lymphocytes 26 (CTL) after the development of antigen-specific immunity[64]. Together with IL-12, IFNy 27 helps drive the differentiation of Th1 cells, which in turn can secrete IL-2, TNF α , and 28 IFNy [65]. The observed lack of circulating IFNy (Figure 1; Table 2) in the plasma of 29 COVID19 patients suggests either severe immune dysfunction or exhaustion. We 30 observed no significant difference in the levels of IL-12 (-19%), or TNF α (3%), in 31 individuals with long-COVID.

32

33 Levels of IL-2 and IL-4 were decreased by 46% and 26%, respectively, in individuals 34 with long-COVID (Figure 1: Table 2). It is possible that fewer T cells differentiated into Th2 cells due to lower levels of IL-2 and IL-4, which could potentially lead to lower levels 35 36 of the cytokines that Th2 cells secrete (IL-4, IL-5, IL-6, IL-9, and IL-13). This scenario 37 may be supported by our data as we observed significantly lower levels of IL-4, IL-6, 38 and IL-13 in individuals with long-COVID (Figure 1: Table 2). Additionally, when we 39 compare the long-COVID cohort, which includes only females, to only the females from 40 the healthy cohort, the decrease in IL-5 between females with long-COVID and healthy 41 females becomes statistically significant (p = 0.0323; Figure 3; Table 2). IL-6 is involved 42 in the differentiation of Th17 cells. It is possible that the lower levels of IL-6 we observed 43 in long covid patients hindered the ability of the Th17 cells to properly differentiate. 44 Supporting this possibility, we see significantly lower levels of IL-17 in individuals with 45 long-COVID (p = 0.0082), the main cytokine secreted by Th17 cells.

Plasma cytokine levels reveal deficiencies in IL-8 and gamma IFN in Long-COVID

1 To ensure that none of the reported differences were due to inherent sex differences we 2 compared cytokine levels between males and females within the healthy cohort. From 3 this, we only observed one significant difference, a 42% reduction of IL-2 in healthy 4 males compared to healthy females (Figure 3; Table 3). This sex-associated difference 5 in IL-2 levels between healthy males and females informed us that the most accurate 6 way to analyze IL-2 levels in our long-COVID cohort was to only consider healthy 7 female IL-2 values. Analyzed in this way, long-COVID females show a 55% reduction in 8 IL-2 levels (p = 0.0028; Figure 2; Table 2). The comparison including both males and 9 females in the healthy cohort is also significant, although the inherently lower values in 10 males complicate the interpretation. 11 12 Additionally, having re-analyzed the data to only include healthy females, it became 13 clear that the differences that we observe between the long-COVID females, and the 14 entire healthy population are not due solely to sex-specific differences in cytokine levels. 15 In fact, the only cytokine that differed in having statistical significance between the healthy female to long-COVID female comparison, and the healthy male + female to 16 17 long-COVID female comparison was IL-5. The removal of the male values from the analysis caused the percent change between the healthy males + females and the long-18 19 COVID females to increase from 14% to 26% (between the healthy females and long-20 COVID females) with a p-value of 0.0323 (Table 2; Figures 2 and 3). 21 22 Earlier we described the heterogeneous nature of the symptoms and cytokines 23 associated with ME/CFS. Even though the symptoms of long-COVID are thought to be 24 similar or overlapping to those of ME/CFS, when we compare our long-COVID cytokine results to those from ME/CFS patients there are glaring differences. Specifically, the 25 26 pro-inflammatory cytokines IL-1 β , TNF α , and IL-6 tend to be reported as being elevated 27 in patients with ME/CFS[32], whereas we observed significant decreases in IL-6 levels 28 in individuals with long-COVID, and no differences in levels of IL-1 β and TNF α . A 29 detailed comparison of cytokines levels published in the context of ME/CFS[32] and our 30 long-COVID levels is provided in Supplementary Table 1. 31

32 Conclusions

Based on our results we propose that immune exhaustion perpetuates long-COVID due
to the seemingly complete reduction of IFNγ and IL-8, as well as significant decreases
in IL-2, IL-4, IL-6, IL-13, and IL-17. Identifying these and other deficiencies will provide
clues towards methods to intervene and possibly restore immune function in the context
of long-COVID. Although functional assays that test the ability of immune cells from
individuals with long-COVID to respond to pathogenic stimuli will be required to support
this theory.

- 40
- 41 42
- 42
- 43
- 44

Plasma cytokine levels reveal deficiencies in IL-8 and gamma IFN in Long-COVID

- 1 2
 - Funding: This work was supported by the University of Utah Inflammation,
- 3 Immunology, & Infectious Diseases (3i) Initiative's Emerging Infectious Diseases
- 4 Fellowship (recipient, ESCPW) and by a seed grant from the University of Utah Vice
- 5 President for Research and the Immunology, Inflammation, and Infectious Disease
- 6 Initiative (recipient, VP). VP and MC were supported by NIH GRANT 5R01-AI143567.
- 7

8 **CRediT author statement**

- 9 Elizabeth S. C. P. Williams: Conceptualization, methodology, formal analysis, data
- 10 curation, writing original draft, visualization, funding acquisition, project administration
- 11 **Thomas Martins:** Investigation, resources
- 12 Harry Hill: Investigation
- 13 Mayte Coiras: Conceptualization, writing review & editing
- 14 **Kevin Shah**: writing review & editing
- 15 Vicente Planelles: Conceptualization, visualization, writing review & editing,
- 16 supervision, project administration
- Adam Spivak: Conceptualization, visualization, writing review & editing
 18

19 Ethics statements

- 20
- 21 Blood samples from donors in both our healthy and long-COVID cohorts were collected
- 22 from individuals who were recruited in compliance with University of Utah Institutional
- 23 Review Board (IRB) protocols 131664 and 140978, respectively.
- 24
- 25

26 References

- 27 [1] CDC Museum COVID-19 Timeline. <u>https://www.cdc.gov/museum/timeline/covid19.htm</u>.
- 28 (Accessed January 5 2022).
- 29 [2] COVID-19 Dashboard. <u>https://coronavirus.jhu.edu/map.html</u>. (Accessed June 18th 2022).
- 30 [3] C. Chen, S.R. Haupert, L. Zimmermann, X. Shi, L.G. Fritsche, B. Mukherjee, Global Prevalence
- of Post COVID-19 Condition or Long COVID: A Meta-Analysis and Systematic Review, J Infect Dis
- 32 (2022).

- 1 [4] S. Lopez-Leon, T. Wegman-Ostrosky, C. Perelman, R. Sepulveda, P.A. Rebolledo, A. Cuapio, S.
- 2 Villapol, More than 50 long-term effects of COVID-19: a systematic review and meta-analysis, Sci Rep 11(1) (2021) 16144.
- 3
- 4 [5] C. Fernandez-de-Las-Penas, D. Palacios-Cena, V. Gomez-Mayordomo, M.L. Cuadrado, L.L.
- 5 Florencio, Defining Post-COVID Symptoms (Post-Acute COVID, Long COVID, Persistent Post-
- 6 COVID): An Integrative Classification, Int J Environ Res Public Health 18(5) (2021).
- 7 [6] N. Nabavi, Long covid: How to define it and how to manage it, BMJ 370 (2020) m3489.
- 8 [7] M.J. Peluso, J. Donatelli, T.J. Henrich, Long-term immunologic effects of SARS-CoV-2
- 9 infection: leveraging translational research methodology to address emerging questions, Transl
- 10 Res (2021).
- 11 [8] A. Malkova, I. Kudryavtsev, A. Starshinova, D. Kudlay, Y. Zinchenko, A. Glushkova, P.
- 12 Yablonskiy, Y. Shoenfeld, Post COVID-19 Syndrome in Patients with Asymptomatic/Mild Form,
- 13 Pathogens 10(11) (2021).
- 14 [9] M. Peghin, A. Palese, M. Venturini, M. De Martino, V. Gerussi, E. Graziano, G. Bontempo, F.
- 15 Marrella, A. Tommasini, M. Fabris, F. Curcio, M. Isola, C. Tascini, Post-COVID-19 symptoms 6
- 16 months after acute infection among hospitalized and non-hospitalized patients, Clinical
- 17 microbiology and infection : the official publication of the European Society of Clinical
- 18 Microbiology and Infectious Diseases 27(10) (2021) 1507-1513.
- 19 [10] M.S.A. Samuel R. Dominguez, Mary P. Glode, Christine C. Robinson, and Kathryn V. Holmes,
- 20 Blinded Case-Control Study of the rElationship between Human Coronavirus NL63 ad Kawasaki
- 21 Syndrome, The Journal of Infectious Diseases 194 (2006).
- 22 [11] K. Shirato, Y. Imada, M. Kawase, K. Nakagaki, S. Matsuyama, F. Taguchi, Possible
- 23 involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease, J
- 24 Med Virol 86(12) (2014) 2146-53.
- 25 [12] H. Algahtani, A. Subahi, B. Shirah, Neurological Complications of Middle East Respiratory
- 26 Syndrome Coronavirus: A Report of Two Cases and Review of the Literature, Case Rep Neurol 27 Med 2016 (2016) 3502683.
- 28 [13] M.L. Catherine M. Tansey, Mark Loeb, Wayne L. Gold, Matthew P. Muller, JoAnne de Jager,
- 29 Jill I. Cameron, George Tomlinson, Tony Mazzulli, Sharon L. Walmsley, Anita R. Rachlis, Barbara
- 30 D. Mederski, Mike Silverman, Zev Shainhouse, Issa E. Ephtimios, Monica Avendano, James
- 31 Downey, Rima Styra, Deborah Yamamura, Marvin Gerson, Matthew B. Stanbrook, Theodore K.
- 32 Marras, Elizabeth J. Phillips, Noe Zamel, Susan E. Richardson, Arthur S. Slutsky, Margaret S.
- 33 Herridge, One-Year Outcomes and Health Care Utilization in Survivors of Severe Acute
- 34 Respiratory Syndrome, Arch Intern Med 167 (2007).
- 35 [14] P.J. Gardner, P. Moallef, Psychological impact on SARS survivors: Critical review of the
- 36 English language literature, Canadian Psychology/Psychologie canadienne 56(1) (2015) 123-135.
- 37 [15] H. Moldofsky, J. Patcai, Chronic widespread musculoskeletal pain, fatigue, depression and
- 38 disordered sleep in chronic post-SARS syndrome; a case-controlled study, BMC Neurol 11
- 39 (2011) 37.
- 40 [16] H.C.C. Kang Sim, The psychological impact of SARS: a matter of heart and mind, Journal of
- 41 Canadian Medical Association 170 (2004).
- 42 [17] J.Z. KS Chan, YW Mok, YM Li, Y-N Liu, CM Chu, MS Ip, SARS: prognosis, outcome and
- 43 sequelae, Respirology 8 (2003).

- 1 [18] H. Jung, S.Y. Jung, M.H. Lee, M.S. Kim, Assessing the Presence of Post-Traumatic Stress and
- 2 Turnover Intention Among Nurses Post-Middle East Respiratory Syndrome Outbreak: The
- 3 Importance of Supervisor Support, Workplace Health Saf 68(7) (2020) 337-345.
- 4 [19] S. Batawi, N. Tarazan, R. Al-Raddadi, E. Al Qasim, A. Sindi, S. Al Johni, F.M. Al-Hameed, Y.M.
- 5 Arabi, T.M. Uyeki, B.M. Alraddadi, Quality of life reported by survivors after hospitalization for
- 6 Middle East respiratory syndrome (MERS), Health Qual Life Outcomes 17(1) (2019) 101.
- 7 [20] S.H. Lee, H.S. Shin, H.Y. Park, J.L. Kim, J.J. Lee, H. Lee, S.D. Won, W. Han, Depression as a
- 8 Mediator of Chronic Fatigue and Post-Traumatic Stress Symptoms in Middle East Respiratory
- 9 Syndrome Survivors, Psychiatry Investig 16(1) (2019) 59-64.
- 10 [21] O. O'Sullivan, Long-term sequelae following previous coronavirus epidemics, Clin Med
- 11 (Lond) 21(1) (2021) e68-e70.
- 12 [22] A. Duvignaud, A. Fianu, A. Bertolotti, J. Jaubert, A. Michault, P. Poubeau, A. Fred, M.
- 13 Mechain, B.A. Gauzere, F. Favier, D. Malvy, P. Gerardin, Rheumatism and chronic fatigue, the
- 14 two facets of post-chikungunya disease: the TELECHIK cohort study on Reunion island,
- 15 Epidemiol Infect 146(5) (2018) 633-641.
- 16 [23] M. Foissac, E. Javelle, S. Ray, B. Guerin, F. Simon, Post-Chikungunya rheumatoid arthritis,
- 17 Saint Martin, Emerg Infect Dis 21(3) (2015) 530-2.
- 18 [24] H.A. Imad, W. Matsee, S. Kludkleeb, P. Asawapaithulsert, J. Phadungsombat, E.E.
- 19 Nakayama, K. Suzuki, P. Leaungwutiwong, W. Piyaphanee, W. Phumratanaprapin, T. Shioda,
- 20 Post-Chikungunya Virus Infection Musculoskeletal Disorders: Syndromic Sequelae after an
- 21 Outbreak, Trop Med Infect Dis 6(2) (2021).
- 22 [25] E. Javelle, A. Ribera, I. Degasne, B.A. Gauzere, C. Marimoutou, F. Simon, Specific
- 23 management of post-chikungunya rheumatic disorders: a retrospective study of 159 cases in
- 24 Reunion Island from 2006-2012, PLoS Negl Trop Dis 9(3) (2015) e0003603.
- 25 [26] M. Hornig, C.G. Gottschalk, M.L. Eddy, X. Che, J.E. Ukaigwe, D.L. Peterson, W.I. Lipkin,
- 26 Immune network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue
- syndrome with atypical and classical presentations, Transl Psychiatry 7(4) (2017) e1080.
- 28 [27] J.G. Montoya, T.H. Holmes, J.N. Anderson, H.T. Maecker, Y. Rosenberg-Hasson, I.J.
- 29 Valencia, L. Chu, J.W. Younger, C.M. Tato, M.M. Davis, Cytokine signature associated with
- 30 disease severity in chronic fatigue syndrome patients, Proc Natl Acad Sci U S A 114(34) (2017)
- 31 E7150-E7158.
- 32 [28] J.G.M. Mady Hornig, Nancy G. Klimas, Susan Levine, Donna Felsenstein, Lucinda Bateman,
- 33 Daniel L. Peterson, C. Gunnar Gottschalk, Andrew F. Schultz, Xiaoyu Che, Meredith L. Eddy,
- 34 Anthony L. Komaroff, W. Ian Lipkin, Distinct plasma immune signatures in ME/CFS are present
- 35 early in the course of illness, Sci Adv (2015).
- 36 [29] U.S. Deumer, A. Varesi, V. Floris, G. Savioli, E. Mantovani, P. Lopez-Carrasco, G.M. Rosati, S.
- 37 Prasad, G. Ricevuti, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): An
- 38 Overview, J Clin Med 10(20) (2021).
- 39 [30] B.M. Carruthers, M.I. van de Sande, K.L. De Meirleir, N.G. Klimas, G. Broderick, T. Mitchell,
- 40 D. Staines, A.C. Powles, N. Speight, R. Vallings, L. Bateman, B. Baumgarten-Austrheim, D.S. Bell,
- 41 N. Carlo-Stella, J. Chia, A. Darragh, D. Jo, D. Lewis, A.R. Light, S. Marshall-Gradisnik, I. Mena, J.A.
- 42 Mikovits, K. Miwa, M. Murovska, M.L. Pall, S. Stevens, Myalgic encephalomyelitis: International
- 43 Consensus Criteria, J Intern Med 270(4) (2011) 327-38.

- 1 [31] J.B. Prins, J.W.M. van der Meer, G. Bleijenberg, Chronic fatigue syndrome, The Lancet
- 2 367(9507) (2006) 346-355.
- 3 [32] S. Blundell, K.K. Ray, M. Buckland, P.D. White, Chronic fatigue syndrome and circulating
- 4 cytokines: A systematic review, Brain Behav Immun 50 (2015) 186-195.
- 5 [33] E. Sweetman, A. Noble, C. Edgar, A. Mackay, A. Helliwell, R. Vallings, M. Ryan, W. Tate,
- 6 Current Research Provides Insight into the Biological Basis and Diagnostic Potential for Myalgic
- 7 Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), Diagnostics (Basel) 9(3) (2019).
- 8 [34] E.R. Sweetman, Margaret; Edgar, Christina; MacKay, Angus; Vallings, Rosamund; Tate,
- 9 Warren, Changes in the transcriptome of circulating immune cells of a New Zealand cohort with
- 10 myalgic encephalomyelitis/ chronic fatigue syndrome, International Journal of
- 11 Immunopathology and Pharmacology 33 (2019).
- 12 [35] E.W. Brenu, K.J. Ashton, J. Batovska, D.R. Staines, S.M. Marshall-Gradisnik, High-throughput
- 13 sequencing of plasma microRNA in chronic fatigue syndrome/myalgic encephalomyelitis, PLoS
- 14 One 9(9) (2014) e102783.
- 15 [36] J.W. Gow, S. Hagan, P. Herzyk, C. Cannon, P.O. Behan, A. Chaudhuri, A gene signature for
- 16 post-infectious chronic fatigue syndrome, BMC Med Genomics 2 (2009) 38.
- 17 [37] C.B. Nguyen, L. Alsoe, J.M. Lindvall, D. Sulheim, E. Fagermoen, A. Winger, M. Kaarbo, H.
- 18 Nilsen, V.B. Wyller, Whole blood gene expression in adolescent chronic fatigue syndrome: an
- exploratory cross-sectional study suggesting altered B cell differentiation and survival, J Transl
- 20 Med 15(1) (2017) 102.
- 21 [38] G.K. Broderick, Ben Z; Fernandes, Henrique; Fletcher, Mary Ann; Klimas, Nancy; Smith,
- 22 Frederick A; O'Gorman, Maurice RG; Vernon, Suzanne D; Taylor, Renee, cytokine expression
- 23 profiles of immune imbalance in post-mononucleosis chronic fatigue, Journal of Translational
- 24 Medicine 10 (2012).
- 25 [39] O. Fluge, O. Mella, O. Bruland, K. Risa, S.E. Dyrstad, K. Alme, I.G. Rekeland, D. Sapkota, G.V.
- Rosland, A. Fossa, I. Ktoridou-Valen, S. Lunde, K. Sorland, K. Lien, I. Herder, H. Thurmer, M.E.
- 27 Gotaas, K.A. Baranowska, L.M. Bohnen, C. Schafer, A. McCann, K. Sommerfelt, L. Helgeland,
- 28 P.M. Ueland, O. Dahl, K.J. Tronstad, Metabolic profiling indicates impaired pyruvate
- dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome, JCI Insight 1(21)(2016) e89376.
- 31 [40] R.K. Naviaux, J.C. Naviaux, K. Li, A.T. Bright, W.A. Alaynick, L. Wang, A. Baxter, N. Nathan,
- 32 W. Anderson, E. Gordon, Metabolic features of chronic fatigue syndrome, Proc Natl Acad Sci U S
- 33 A 113(37) (2016) E5472-80.
- 34 [41] A. Proal, T. Marshall, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in the Era of
- 35 the Human Microbiome: Persistent Pathogens Drive Chronic Symptoms by Interfering With
- 36 Host Metabolism, Gene Expression, and Immunity, Front Pediatr 6 (2018) 373.
- 37 [42] E. Yamano, Y. Watanabe, Y. Kataoka, Insights into Metabolite Diagnostic Biomarkers for
- 38 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Int J Mol Sci 22(7) (2021).
- 39 [43] C. Tomas, A. Brown, V. Strassheim, J.L. Elson, J. Newton, P. Manning, Cellular bioenergetics
- 40 is impaired in patients with chronic fatigue syndrome, PLoS One 12(10) (2017) e0186802.
- 41 [44] W.C. de Vega, S. Herrera, S.D. Vernon, P.O. McGowan, Epigenetic modifications and
- 42 glucocorticoid sensitivity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS),
- 43 BMC Med Genomics 10(1) (2017) 11.

- 1 [45] N. Navaneetharaja, V. Griffiths, T. Wileman, S.R. Carding, A Role for the Intestinal
- 2 Microbiota and Virome in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)?, J
- 3 Clin Med 5(6) (2016).
- 4 [46] L. Giloteaux, J.K. Goodrich, W.A. Walters, S.M. Levine, R.E. Ley, M.R. Hanson, Reduced
- 5 diversity and altered composition of the gut microbiome in individuals with myalgic
- 6 encephalomyelitis/chronic fatigue syndrome, Microbiome 4(1) (2016) 30.
- 7 [47] F. Newberry, S.Y. Hsieh, T. Wileman, S.R. Carding, Does the microbiome and virome
- 8 contribute to myalgic encephalomyelitis/chronic fatigue syndrome?, Clin Sci (Lond) 132(5)
- 9 (2018) 523-542.
- 10 [48] M. Ruiz-Pablos, B. Paiva, R. Montero-Mateo, N. Garcia, A. Zabaleta, Epstein-Barr Virus and
- the Origin of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome, Front Immunol 12 (2021)656797.
- 13 [49] E. Shikova, V. Reshkova, C. Kumanova capital A, S. Raleva, D. Alexandrova, N. Capo, M.
- 14 Murovska, M.C. European Network on, Cytomegalovirus, Epstein-Barr virus, and human
- 15 herpesvirus-6 infections in patients with myalgic small ie, Cyrillicncephalomyelitis/chronic
- 16 fatigue syndrome, J Med Virol (2020).
- 17 [50] M.E. Ariza, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Human
- 18 Herpesviruses Are Back!, Biomolecules 11(2) (2021).
- 19 [51] M. Cortes Rivera, C. Mastronardi, C.T. Silva-Aldana, M. Arcos-Burgos, B.A. Lidbury, Myalgic
- 20 Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review, Diagnostics (Basel)21 9(3) (2019).
- 22 [52] T.B. Martins, B.M. Pasi, C.M. Litwin, H.R. Hill, Heterophile antibody interference in a
- 23 multiplexed fluorescent microsphere immunoassay for quantitation of cytokines in human
- 24 serum, Clin Diagn Lab Immunol 11(2) (2004) 325-9.
- 25 [53] T.B. Martins, R. Burlingame, C.A. von Muhlen, T.D. Jaskowski, C.M. Litwin, H.R. Hill,
- 26 Evaluation of multiplexed fluorescent microsphere immunoassay for detection of
- autoantibodies to nuclear antigens, Clin Diagn Lab Immunol 11(6) (2004) 1054-9.
- 28 [54] M. Patel, F. Shahjin, J.D. Cohen, M. Hasan, J. Machhi, H. Chugh, S. Singh, S. Das, T.A.
- 29 Kulkarni, J. Herskovitz, D.D. Meigs, R. Chandra, K.S. Hettie, R.L. Mosley, B.D. Kevadiya, H.E.
- 30 Gendelman, The Immunopathobiology of SARS-CoV-2 Infection, FEMS Microbiol Rev 45(6)
- 31 (2021).
- 32 [55] C.S. Shi, N.R. Nabar, N.N. Huang, J.H. Kehrl, SARS-Coronavirus Open Reading Frame-8b
- triggers intracellular stress pathways and activates NLRP3 inflammasomes, Cell Death Discov 5
 (2019) 101.
- 35 [56] G.a.G. Zhang, Sankar, Toll-like receptor-mediated NF-kB activation: a phylogenetically
- 36 cnserved paradigm in innate immunity, The Journal of Clinical Investigation 107 (2001).
- 37 [57] V.A. Ryabkova, L.P. Churilov, Y. Shoenfeld, Influenza infection, SARS, MERS and COVID-19:
- 38 Cytokine storm The common denominator and the lessons to be learned, Clin Immunol 223
- 39 (2021) 108652.
- 40 [58] <SSRN-id3527420.pdf>.
- 41 [59] T.a.R. Nguyen, John, The regulation of FasL expression during activation-induced cell death
- 42 (AICD), Immunology 103 (2001).

18

- 1 [60] A. Jafarzadeh, P. Chauhan, B. Saha, S. Jafarzadeh, M. Nemati, Contribution of monocytes
- 2 and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons
- 3 from SARS and MERS, and potential therapeutic interventions, Life Sci 257 (2020) 118102.
- 4 [61] D. Wu, X.O. Yang, TH17 responses in cytokine storm of COVID-19: An emerging target of
- 5 JAK2 inhibitor Fedratinib, J Microbiol Immunol Infect 53(3) (2020) 368-370.
- 6 [62] M. Baggiolini, A. Walz, S.L. Kunkel, Neutrophil-activating peptide-1/interleukin 8, a novel
- 7 cytokine that activates neutrophils, J Clin Invest 84(4) (1989) 1045-9.
- 8 [63] M. Metzemaekers, M. Gouwy, P. Proost, Neutrophil chemoattractant receptors in health
- 9 and disease: double-edged swords, Cellular & molecular immunology 17(5) (2020) 433-450.
- 10 [64] J.R. Schoenborn, C.B. Wilson, Regulation of interferon-gamma during innate and adaptive
- 11 immune responses, Advances in immunology 96 (2007) 41-101.
- 12 [65] A. Ray, Cytokines and their Role in Health and Disease: A Brief Overview, MOJ Immunology
- 13 **4(2) (2016)**.
- 14
- 15

- 1 Supplemental Figure 1. Comparison of publications depicting cytokine fluctuation in
- 2 ME/CFS and our long-COVID cytokine results.

Cytokine	Higher in ME/CFS	Lower in ME/CFS	No Change	Total Studies	Long- COVID				
Pro-inflammatory									
IL-1b	7 (28%) [1- 7]	0	18 (72%) [8-25]	25	NC				
TNFa	4 (15%) [1, 2, 5, 21]	0	22 (85%) [4, 6-20, 22, 24-28]	26	NC				
IL-6	6 (24%) [1, 4, 6, 7, 11, 29]	2 (8%) [2, 9]	17 (68%) [8, 10, 12-16, 18, 19, 21, 23, 24, 26, 30-33]	25	Down				
Anti-inflam	matory								
IL-10	2 (13%) [1, 2]	1 (6%) [9]	12 (81%) [4, 6-8, 11-16, 18, 28]	15	NC				
IL-13	1 (16%) [1]	0	5 (84%) [6-9, 13- 15]	6	Down				
Th1									
IL-2	2 (14%) [11, 13]	0	12 (86%) [1, 4, 7- 9, 13-15, 18, 21, 25, 34]	14	Down				
IL-12	3 (30%) [1, 7, 11]	0	7 (70%) [6, 8, 9, 13-15, 18]	10	NC				
IFNγ	2 (13%) [1, 11]	1 (6%) [2]	12 (81%) [6-10, 13-15, 22, 23, 25, 28]	15	Down to 0				
Th2									
IL-5	1 (14%) [7]	1 (14%) [1]	5 (72%) [8, 9, 11, 13, 14]	7	NC				
IL-4	2 (18%) [1, 7]	0	9 (82%) [8, 9, 11- 16, 21]	11	Down				
Th17									
IL-17	0	2 (33%) [1, 9]	4 (66%) [7, 8, 13, 14]	6	Down				
NK-cell attractant									
IL-8	3 <i>(23%)</i> [2, 6, 14]	3 <i>(</i> 23%) [1, 7, 9]	7 (54%) [8, 11-13, 15, 16, 29]	13	Down to 0				

Plasma cytokine levels reveal deficiencies in IL-8 and gamma IFN in Long-COVID

- 1 Adapted from Blundell *et al.* 2015[35]. There is no agreement regarding changes in cytokine
- 2 levels associated with ME/CFS. Although studies that do report changes tend to report
- 3 cytokines as being upregulated in ME/CFS as compared to our long-COVID cytokine data
- 4 showing significant decreases in cytokine levels.
- 5

6 Supplemental References:

- 7
- 8 [1] S.F. Khaiboullina, K.L. DeMeirleir, S. Rawat, G.S. Berk, R.S. Gaynor-Berk, T. Mijatovic, N. Blatt,
- 9 A.A. Rizvanov, S.G. Young, V.C. Lombardi, Cytokine expression provides clues to the
- 10 pathophysiology of Gulf War illness and myalgic encephalomyelitis, Cytokine 72(1) (2015) 1-8.
- 11 [2] D. Neu, O. Mairesse, X. Montana, M. Gilson, F. Corazza, N. Lefevre, P. Linkowski, O. Le Bon,
- 12 P. Verbanck, Dimensions of pure chronic fatigue: psychophysical, cognitive and biological
- 13 correlates in the chronic fatigue syndrome, Eur J Appl Physiol 114(9) (2014) 1841-51.
- 14 [3] M. Maes, K. Ringel, M. Kubera, G. Anderson, G. Morris, P. Galecki, M. Geffard, In myalgic
- 15 encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity against 5-HT is
- 16 associated with immuno-inflammatory pathways and bacterial translocation, J Affect Disord
- 17 150(2) (2013) 223-30.
- 18 [4] E.G. Lattie, M.H. Antoni, M.A. Fletcher, F. Penedo, S. Czaja, C. Lopez, D. Perdomo, A. Sala, S.
- 19 Nair, S.H. Fu, N. Klimas, Stress management skills, neuroimmune processes and fatigue levels in
- 20 persons with chronic fatigue syndrome, Brain Behav Immun 26(6) (2012) 849-58.
- 21 [5] M. Maes, F.N. Twisk, M. Kubera, K. Ringel, Evidence for inflammation and activation of cell-
- 22 mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS):
- 23 increased interleukin-1, tumor necrosis factor-alpha, PMN-elastase, lysozyme and neopterin, J
- 24 Affect Disord 136(3) (2012) 933-9.
- 25 [6] P. Scully, D.P. McKernan, J. Keohane, D. Groeger, F. Shanahan, T.G. Dinan, E.M. Quigley,
- 26 Plasma Cytokine Profiles in Females With Irritable Bowel Syndrome and Extra-Intestinal Co-
- 27 Morbidity, Official journal of the American College of Gastroenterology | ACG 105(10) (2010)
- 28 2235-2243.
- 29 [7] M.A. Fletcher, X.R. Zeng, Z. Barnes, S. Levis, N.G. Klimas, Plasma cytokines in women with
- 30 chronic fatigue syndrome, J Transl Med 7 (2009) 96.
- 31 [8] V.B. Wyller, O. Sorensen, D. Sulheim, E. Fagermoen, T. Ueland, T.E. Mollnes, Plasma cytokine
- 32 expression in adolescent chronic fatigue syndrome, Brain Behav Immun 46 (2015) 80-6.
- 33 [9] J.G.M. Mady Hornig, Nancy G. Klimas, Susan Levine, Donna Felsenstein, Lucinda Bateman,
- 34 Daniel L. Peterson, C. Gunnar Gottschalk, Andrew F. Schultz, Xiaoyu Che, Meredith L. Eddy,
- Anthony L. Komaroff, W. Ian Lipkin, Distinct plasma immune signatures in ME/CFS are present early in the course of illness, Sci Adv (2015).
- 37 [10] Y. Nakatomi, K. Mizuno, A. Ishii, Y. Wada, M. Tanaka, S. Tazawa, K. Onoe, S. Fukuda, J.
- 38 Kawabe, K. Takahashi, Y. Kataoka, S. Shiomi, K. Yamaguti, M. Inaba, H. Kuratsune, Y. Watanabe,
- 39 Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An
- 40 (1)(1)C-(R)-PK11195 PET Study, J Nucl Med 55(6) (2014) 945-50.
- 41 [11] M.N. Garcia, A.M. Hause, C.M. Walker, J.S. Orange, R. Hasbun, K.O. Murray, Evaluation of
- 42 prolonged fatigue post-West Nile virus infection and association of fatigue with elevated
- 43 antiviral and proinflammatory cytokines, Viral immunology 27(7) (2014) 327-33.

- 1 [12] T. Nakamura, S. Schwander, R. Donnelly, D.B. Cook, F. Ortega, F. Togo, Y. Yamamoto, N.S.
- 2 Cherniack, M. Klapholz, D. Rapoport, B.H. Natelson, Exercise and sleep deprivation do not
- change cytokine expression levels in patients with chronic fatigue syndrome, Clinical and
 vaccine immunology : CVI 20(11) (2013) 1736-42.
- 5 [13] G.B. Anne Liese Smylie , Henrique Fernandes , Shirin Razdan , Zachary Barnes , Fanny
- 6 Collado , Connie Sol , Mary Ann Fletcher and Nancy Klimas, A comparison of sex-specific
- 7 immune signatures in Gulf War illness and chronic fatigue syndrome, BMC Immunology 14
- 8 (2013).
- 9 [14] G.K. Broderick, Ben Z; Fernandes, Henrique; Fletcher, Mary Ann; Klimas, Nancy; Smith,
- 10 Frederick A; O'Gorman, Maurice RG; Vernon, Suzanne D; Taylor, Renee, cytokine expression
- 11 profiles of immune imbalance in post-mononucleosis chronic fatigue, Journal of Translational
- 12 Medicine 10 (2012).
- 13 [15] A.T. White, A.R. Light, R.W. Hughen, L. Bateman, T.B. Martins, H.R. Hill, K.C. Light, Severity
- 14 of symptom flare after moderate exercise is linked to cytokine activity in chronic fatigue
- 15 syndrome, Psychophysiology 47(4) (2010) 615-24.
- 16 [16] T. Nakamura, S.K. Schwander, R. Donnelly, F. Ortega, F. Togo, G. Broderick, Y. Yamamoto,
- 17 N.S. Cherniack, D. Rapoport, B.H. Natelson, Cytokines across the night in chronic fatigue
- syndrome with and without fibromyalgia, Clinical and vaccine immunology : CVI 17(4) (2010)582-7.
- 20 [17] V.A. Spence, G. Kennedy, J.J. Belch, A. Hill, F. Khan, Low-grade inflammation and arterial
- 21 wave reflection in patients with chronic fatigue syndrome, Clin Sci (Lond) 114(8) (2008) 561-6.
- 22 [18] U. Vollmer-Conna, B. Cameron, D. Hadzi-Pavlovic, K. Singletary, T. Davenport, S. Vernon,
- 23 W.C. Reeves, I. Hickie, D. Wakefield, A.R. Lloyd, G. Dubbo Infective Outcomes Study,
- 24 Postinfective fatigue syndrome is not associated with altered cytokine production, Clin Infect
- 25 Dis 45(6) (2007) 732-5.
- 26 [19] K.L. MacDonald, T.O. Michael, K.H. LeDell, K.E. White, C.H. Schenck, C.C. Chao, D.H. Persing,
- 27 R.C. Johnson, J.M. Barker, P.K. Peterson, A case-Control Study to Assess Possible Triggers and
- 28 Cofactors in Chronic Fatigue Syndrome, The American Journal of Medicine 100 (1996).
- 29 [20] C.M.A. Swanink, J.H.M.M. Vercoulen, J.M.D. Galama, M.T.L. Roos, L. Meyaard, J.v.d. Ven-
- 30 Jongekrijg, R.d. Nijs, G. Bleijenberg, J.F.M. Fennis, F. Miedema, Lymphocyte subsets, apoptosis,
- and cytokines in patients with chronic fatigue syndrome, Journal of Infectous Diseases 173(2)
 (1996).
- 33 [21] R. Patarca, N.G. Klimas, S. Lugtendorf, M. Antoni, M.A. Fletcher, Dysregulated Expression of
- 34 Tumor Necrosis Factor in Chronic Fatigue Syndrome: Interrelations with Cellular Sources and
- 35 Patterns of Soluble Immune Mediator Expression, Clinical Infectious Diseases
- 36 18(Supplement_1) (1994) S147-S153.
- 37 [22] A. Lloyd, S. Gandevia, A. Brockman, J. Hales, D. Wakefield, Cytokine Production and Fatigue
- 38 in Patients with Chronic Fatigue Syndrome and Healthy Control Subjects in Response to
- 39 Exercise, Clinical Infectious Diseases 18(Supplement_1) (1994) S142-S146.
- 40 [23] A. Linde, B. Andersson, S.B. Svenson, H. Ahrne, M. Carlsson, P. Forsberg, H. Hugo, A.
- 41 Karstorp, R. Lenkei, A. Lindwall, A. Loftenius, C. Säil, J. Andersson, Serum Levels of Lymphokines
- 42 and Soluble Cellular Receptors in Primary Epstein-Barr Virus Infection and in Patients with
- 43 Chronic Fatigue Syndrome, The Journal of Infectious Diseases 165(6) (1992) 994-1000.

- 1 [24] C.C. Chao, E.N. Janoff, S.X. Hu, K. Thomas, M. Gallagher, M. Tsang, P.K. Peterson, Altered
- cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic
 fatigue syndrome, Cytokine 3(4) (1991) 292-8.
- 4 [25] S.E. Straus, J.K. Dale, J.B. Peter, C.A. Dinarello, Circulating Lymphokine Levels in the Chronic
- 5 Fatigue Syndrome, The Journal of Infectious Diseases 160(6) (1989) 1085-1086.
- 6 [26] Y. Jammes, J.G. Steinberg, S. Delliaux, F. Bregeon, Chronic fatigue syndrome combines
- 7 increased exercise-induced oxidative stress and reduced cytokine and Hsp responses, J Intern
- 8 Med 266(2) (2009) 196-206.
- 9 [27] P.D. White, K.E. Nye, A.J. Pinching, T.M. Yap, N. Power, V. Vleck, D.J. Bentley, J.M. Thomas,
- 10 M. Buckland, J.M. Parkin, Immunological Changes After Both Exercise and Activity in Chronic
- 11 Fatigue Syndrome, Journal of Chronic Fatigue Syndrome 12(2) (2004) 51-66.
- 12 [28] J. Visser, W. Graffelman, B. Blauw, I. Haspels, E. Lentijes, E.R.d. Kloet, L. Nagelkerken, LPS-
- 13 induced IL-10 production in whole blood cultures from chronic fatigue syndrome patients is
- 14 increased but supersensitive to inhibition by dexamethasone, Journal of Neuroimmunology 119
- 15 (2001).
- 16 [29] K. Nas, R. Cevik, S. Batum, A.J. Sarac, S. Acar, S. Kalkanli, Immunologic and psychosocial
- 17 status in chronic fatigue syndrome, Bratisl Lek Listy 112(4) (2011) 208-12.
- 18 [30] M. Robinson, S.R. Gray, M.S. Watson, G. Kennedy, A. Hill, J.J. Belch, M.A. Nimmo, Plasma
- 19 IL-6, its soluble receptors and F2-isoprostanes at rest and during exercise in chronic fatigue
- 20 syndrome, Scand J Med Sci Sports 20(2) (2010) 282-90.
- 21 [31] U.M. Nater, L.S. Youngblood, J.F. Jones, E.R. Unger, A.H. Miller, W.C. Reeves, C. Heim,
- 22 Alterations in diurnal salivary cortisol rhythm in a population-based sample of cases with
- chronic fatigue syndrome, Psychosom Med 70(3) (2008) 298-305.
- 24 [32] J.G. Cannon, J.B. Angel, R.W. Ball, L.W. ABAD, L.R. Fagioli, A.L. Kamaroff, Acute Phase
- Responses and Cytokine Secretion in Chronic Fatigue Syndrome, Journal of Clinical Immunology19 (1999).
- 27 [33] D. Buchwald, M.H. Wener, T. Pearlman, P. Kith, Markers of inflammation and immune
- activation in chronic fatigue and chronic fatigue syndrome, J Rheumatol 24(2) (1997) 372-6.
- 29 [34] P.R. Cheney, S.E. Dorman, D.s. Bell, Interleukin-2 and the Chronic Fatigue Syndrome,
- 30 Annals of Internal Medicine 110 (1989).
- 31 [35] S. Blundell, K.K. Ray, M. Buckland, P.D. White, Chronic fatigue syndrome and circulating
- 32 cytokines: A systematic review, Brain Behav Immun 50 (2015) 186-195.
- 33